TearLab Corporation
12707 High Bluff Drive
Suite 200
San Diego
California
92130
United States
Tel: 858-350-4270
Fax: 858-794-1493
Website: http://www.tearlab.com/
138 articles about TearLab Corporation
-
TearLab® Announces Corporate Name Change to Trukera™ Medical, Positions Company for Further Expansion in Corneal Health
9/7/2022
TearLab® Corporation, the global leader in ophthalmic point-of-care diagnostics, announced that it will be expanding its position in corneal health under the new name Trukera™ Medical.
-
TearLab Closes Acquisition By Accelmed Partners
7/9/2020
TearLab Corporation (TearLab), a leader in diagnostics for dry eye disease (DED), today announced their acquisition by Accelmed Partners II (AP-II). As a newly formed private company, TearLab is now positioned to pursue further devel
-
TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment
5/11/2020
TearLab Corporation, a leader in Ocular Surface Diagnostics, announced it has entered into a definitive agreement pursuant to which Accelmed Partners II will acquire TearLab.
-
TearLab Corporation Confirms Merger Discussions
5/7/2020
In light of recent market rumors, TearLab Corporation confirmed that TearLab is engaged in advanced discussions regarding a potential business combination whereby TearLab will be acquired at a price per share equal to $0.0586.
-
TearLab Resubmits 510(k) for U.S. FDA Clearance of the TearLab Discovery™ MMP-9 Test
4/22/2020
TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its 510(k) application for the potential clearance of its TearLab Discovery™ MMP-9 Test, the Company’s next-generation in-vitro diagnostic testing system.
-
TearLab Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
3/5/2020
TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2019
-
TearLab Corporation Reports Third Quarter 2019 Financial Results
11/7/2019
TearLab Corporation reported its consolidated financial results for the third quarter ended September 30, 2019.
-
TearLab Submits 510(k) for U.S. FDA Clearance of TearLab Discovery Platform
1/4/2018
TearLab Discovery will also be capable of performing the Company’s current FDA cleared tear osmolarity test.
-
TearLab to Cut More Jobs
12/27/2017
TearLab did not report exactly how many employees it will let go -
TearLab Prices $3M Registered Direct Offering
12/6/2017
Each unit consists of one share of TearLab common stock.
-
TearLab Launches Registered Direct Offering
11/30/2017
The Company plans to use the proceeds of this offering for general corporate purposes.
-
TearLab Corporation Reports Third Quarter and September Year-To-Date 2017 Financial Results
11/14/2017
For the three months ended September 30, 2017, TearLab’s net revenues were $6.5 million, compared with $7.2 million for the same period in 2016.
-
TearLab Corporation Begins Trading on OTCQB
11/9/2017
As previously disclosed, the Company was unable to regain compliance with NASDAQ Listing Rule 5550(b) prior to November 6, 2017.
-
TearLab Tweaks Regulatory Strategy for Next-Generation In-Vitro Diagnostics Testing Platform
10/18/2017
Company Remains on-track to submit 510(k) application in 2017. -
TearLab Announces Release Of 2018 - 2020 Preliminary Reimbursement Rates
9/27/2017
-
TearLab Receives Nasdaq Listing Extension
8/31/2017
-
TearLab Reports Second Quarter And First Half 2017 Financial Results
8/15/2017
-
TearLab To Release Second Quarter 2017 Financial Results On August 14, 2017
8/3/2017
-
TearLab Announces European Regulatory Clearance For Next-Generation Tearlab Discovery System
7/21/2017
-
TearLab Receives Nasdaq Listing Extension
6/22/2017